{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:48:38Z","timestamp":1792244918494,"version":"4.4.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100007109","name":"Universit\u00e0 degli Studi di Ferrara","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007109","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>Dopamine agonists (DAs), such as cabergoline (CAB), are first-line treatments for hyperprolactinaemia but have been associated with impulse control disorders (ICD). This observational study aimed to investigate the prevalence, severity, and clinical characteristics of ICD in CAB-treated patients compared with controls, using a combined clinician-administered and multimethod self-report assessment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 126 participants were included: 63 patients with prolactin-secreting pituitary adenomas receiving cabergoline (CAB) and 63 controls (CG). ICD were evaluated using the Parkinson\u2019s Impulse Control Scale (PICS) as the reference diagnostic measure, alongside self-report questionnaires assessing ICD-related behaviors. Psychiatric comorbidity was assessed using the Mini International Neuropsychiatric Interview (MINI), and general psychopathology using the Brief Symptom Inventory-53 (BSI-53).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>ICD were identified in 15.9% of CAB-treated patients and 6.3% of controls, indicating a more than twofold higher prevalence and greater severity in the CAB group, although differences were not statistically significant. When restricted to CAB-related cases, prevalence decreased to 12.7%. The Questionnaire for Impulsive-Compulsive Disorders (QUIP) showed moderate sensitivity (71.4%) but low positive predictive value (41.7%). Within the CAB group, ICD-positive patients had shorter treatment duration and lower weekly doses. No significant differences emerged in MINI or BSI-53 results, although psychiatric comorbidity was present in ~\u200950% of ICD cases.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>CAB therapy was associated with a modest but clinically meaningful increase in ICD. Screening tools may support early identification, but positive findings require confirmation through comprehensive clinical assessment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s11102-026-01693-7","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:31:41Z","timestamp":1779085901000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impulse control disorders and their relationship with psychopathology in patients treated with cabergoline for hyperprolactinaemia"],"prefix":"10.1007","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6821-1005","authenticated-orcid":false,"given":"Luigi","family":"Zerbinati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Cristilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beatrice","family":"Valier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Braccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Okai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso","family":"Toffanin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"Verrienti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonella","family":"Giampietro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luigi","family":"Grassi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Chiara","family":"Zatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Rosaria","family":"Ambrosio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"1693_CR1","doi-asserted-by":"publisher","first-page":"P1","DOI":"10.1530\/EJE-21-0977","volume":"186","author":"R Cozzi","year":"2022","unstructured":"Cozzi R, Ambrosio MR, Attanasio R et al (2022) Italian Association of Clinical Endocrinologists (AME) and International Chapter of Clinical Endocrinology (ICCE). Position statement for clinical practice: prolactin-secreting tumors. Eur J Endocrinol 186:P1\u2013P33. https:\/\/doi.org\/10.1530\/EJE-21-0977","journal-title":"Eur J Endocrinol"},{"key":"1693_CR2","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1001\/archneurol.2010.65","volume":"67","author":"D Weintraub","year":"2010","unstructured":"Weintraub D, Koester J, Potenza MN et al (2010) Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol 67:589\u2013595. https:\/\/doi.org\/10.1001\/archneurol.2010.65","journal-title":"Arch Neurol"},{"key":"1693_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1097\/WNF.0b013e3182281b2f","volume":"34","author":"J Martinkova","year":"2011","unstructured":"Martinkova J, Trejbalova L, Sasikova M et al (2011) Impulse Control Disorders Associated With Dopaminergic Medication in Patients With Pituitary Adenomas. Clin Neuropharmacol 34:179. https:\/\/doi.org\/10.1097\/WNF.0b013e3182281b2f","journal-title":"Clin Neuropharmacol"},{"key":"1693_CR4","doi-asserted-by":"publisher","first-page":"102910","DOI":"10.1016\/j.arcmed.2023.102910","volume":"54","author":"R Hamblin","year":"2023","unstructured":"Hamblin R, Karavitaki N (2023) Impulse Control Disorders in Patients with Pituitary Tumors Treated with Dopamine Agonists: A Systematic Review. Arch Med Res 54:102910. https:\/\/doi.org\/10.1016\/j.arcmed.2023.102910","journal-title":"Arch Med Res"},{"key":"1693_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1111\/cen.12375","volume":"80","author":"I Bancos","year":"2014","unstructured":"Bancos I, Nannenga MR, Bostwick JM et al (2014) Impulse control disorders in patients with dopamine agonist-treated prolactinomas and nonfunctioning pituitary adenomas: a case-control study. Clin Endocrinol (Oxf) 80:863\u2013868. https:\/\/doi.org\/10.1111\/cen.12375","journal-title":"Clin Endocrinol (Oxf)"},{"key":"1693_CR6","doi-asserted-by":"publisher","first-page":"dgz076","DOI":"10.1210\/clinem\/dgz076","volume":"105","author":"SMC De Sousa","year":"2020","unstructured":"De Sousa SMC, Baranoff J, Rushworth RL et al (2020) Impulse Control Disorders in Dopamine Agonist-Treated Hyperprolactinemia: Prevalence and Risk Factors. J Clin Endocrinol Metab 105:dgz076. https:\/\/doi.org\/10.1210\/clinem\/dgz076","journal-title":"J Clin Endocrinol Metab"},{"key":"1693_CR7","doi-asserted-by":"publisher","first-page":"2527","DOI":"10.1210\/jc.2018-02202","volume":"104","author":"SC Dogansen","year":"2019","unstructured":"Dogansen SC, Cikrikcili U, Oruk G et al (2019) Dopamine Agonist-Induced Impulse Control Disorders in Patients With Prolactinoma: A Cross-Sectional Multicenter Study. J Clin Endocrinol Metab 104:2527\u20132534. https:\/\/doi.org\/10.1210\/jc.2018-02202","journal-title":"J Clin Endocrinol Metab"},{"key":"1693_CR8","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1007\/s11102-025-01517-0","volume":"28","author":"R Hamblin","year":"2025","unstructured":"Hamblin R, White M, Fountas A, Karavitaki N (2025) Impulse control disorders in patients with pituitary adenoma managed with or without dopamine agonists: a cross-sectional study from a UK centre. Pituitary 28:52. https:\/\/doi.org\/10.1007\/s11102-025-01517-0","journal-title":"Pituitary"},{"key":"1693_CR9","doi-asserted-by":"publisher","unstructured":"Paribello P, Manchia M, Pinna F, Carpiniello B (2024) Impulsivity, aggressivity and mood disorders: a narrative review. J Psychopathol 30. https:\/\/doi.org\/10.36148\/2284-0249-N460","DOI":"10.36148\/2284-0249-N460"},{"key":"1693_CR10","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1002\/mdc3.12316","volume":"3","author":"D Okai","year":"2016","unstructured":"Okai D, Askey-Jones S, Mack J et al (2016) Parkinson\u2019s Impulse-Control Scale for the Severity Rating of Impulse-Control Behaviors in Parkinson\u2019s Disease: A Semistructured Clinical Assessment Tool. Mov Disorders Clin Pract 3:494\u2013499. https:\/\/doi.org\/10.1002\/mdc3.12316","journal-title":"Mov Disorders Clin Pract"},{"key":"1693_CR11","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1097\/01.jcp.0000139758.03834.ad","volume":"24","author":"A Rossi","year":"2004","unstructured":"Rossi A, Alberio R, Porta A et al (2004) The reliability of the Mini-International Neuropsychiatric Interview\u2013Italian version. J Clin Psychopharmacol 24:561\u2013563. https:\/\/doi.org\/10.1097\/01.jcp.0000139758.03834.ad","journal-title":"J Clin Psychopharmacol"},{"key":"1693_CR12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1159\/000077740","volume":"73","author":"C Faravelli","year":"2004","unstructured":"Faravelli C, Abrardi L, Bartolozzi D et al (2004) The Sesto Fiorentino study: background, methods and preliminary results. Lifetime prevalence of psychiatric disorders in an Italian community sample using clinical interviewers. Psychother Psychosom 73:216\u2013225. https:\/\/doi.org\/10.1159\/000077740","journal-title":"Psychother Psychosom"},{"key":"1693_CR13","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1002\/mds.22571","volume":"24","author":"D Weintraub","year":"2009","unstructured":"Weintraub D, Hoops S, Shea JA et al (2009) Validation of the questionnaire for impulsive-compulsive disorders in Parkinson\u2019s disease. Mov Disord 24:1461\u20131467. https:\/\/doi.org\/10.1002\/mds.22571","journal-title":"Mov Disord"},{"key":"1693_CR14","doi-asserted-by":"publisher","unstructured":"Ciocca G, Nimbi FM, Limoncin E et al (2020) Italian validation of the Hypersexual Behavior Inventory (HBI): psychometric characteristics of a self-report tool evaluating a psychopathological facet of sexual behavior. J Psychopathol 169\u2013175. https:\/\/doi.org\/10.36148\/2284-0249-392","DOI":"10.36148\/2284-0249-392"},{"key":"1693_CR15","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1007\/s11469-019-00167-1","volume":"19","author":"P Iliceto","year":"2021","unstructured":"Iliceto P, Fino E, Schiavella M, Oei TP (2021) Psychometric Properties of the Italian Versions of the Gambling Urge Scale (GUS) and the Gambling Refusal Self-Efficacy Questionnaire (GRSEQ). Int J Ment Health Addict 19:207\u2013226. https:\/\/doi.org\/10.1007\/s11469-019-00167-1","journal-title":"Int J Ment Health Addict"},{"key":"1693_CR16","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/1098-108X(198321)2:2<15::AID-EAT2260020203>3.0.CO;2-6","volume":"2","author":"DM Garner","year":"1983","unstructured":"Garner DM, Olmstead MP, Polivy J (1983) Development and validation of a multidimensional eating disorder inventory for anorexia nervosa and bulimia. Int J Eat Disord 2:15\u201334. https:\/\/doi.org\/10.1002\/1098-108X(198321)2:2%3C15::AID-EAT2260020203%3E3.0.CO;2-6","journal-title":"Int J Eat Disord"},{"key":"1693_CR17","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1086\/209315","volume":"19","author":"RJ Faber","year":"1992","unstructured":"Faber RJ, O\u2019Guinn TC (1992) A Clinical Screener for Compulsive Buying. J Consum Res 19:459\u2013469. https:\/\/doi.org\/10.1086\/209315","journal-title":"J Consum Res"},{"key":"1693_CR18","unstructured":"Derogatis LR (1993) BSI, Brief Symptom Inventory: Administration, Scoring & Procedures Manual. National Computer Systems"},{"key":"1693_CR19","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1007\/s00406-006-0668-0","volume":"256","author":"B Dell\u2019Osso","year":"2006","unstructured":"Dell\u2019Osso B, Altamura AC, Allen A et al (2006) Epidemiologic and clinical updates on impulse control disorders: a critical review. Eur Arch Psychiatry Clin Neurosci 256:464\u2013475. https:\/\/doi.org\/10.1007\/s00406-006-0668-0","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"1693_CR20","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1002\/mds.27689","volume":"34","author":"AH Evans","year":"2019","unstructured":"Evans AH, Okai D, Weintraub D et al (2019) Scales to assess impulsive and compulsive behaviors in Parkinson\u2019s disease: Critique and recommendations. Mov Disord 34:791\u2013798. https:\/\/doi.org\/10.1002\/mds.27689","journal-title":"Mov Disord"},{"key":"1693_CR21","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.parkreldis.2010.11.015","volume":"17","author":"K Papay","year":"2011","unstructured":"Papay K, Mamikonyan E, Siderowf AD et al (2011) Patient versus informant reporting of ICD symptoms in Parkinson\u2019s disease using the QUIP: Validity and variability. Parkinsonism Relat Disord 17:153\u2013155. https:\/\/doi.org\/10.1016\/j.parkreldis.2010.11.015","journal-title":"Parkinsonism Relat Disord"},{"key":"1693_CR22","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1007\/s11154-022-09753-6","volume":"23","author":"A Hamidianjahromi","year":"2022","unstructured":"Hamidianjahromi A, Tritos NA (2022) Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Rev Endocr Metab Disord 23:1089\u20131099. https:\/\/doi.org\/10.1007\/s11154-022-09753-6","journal-title":"Rev Endocr Metab Disord"},{"key":"1693_CR23","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1176\/jnp.2007.19.4.473","volume":"19","author":"M Davie","year":"2007","unstructured":"Davie M (2007) Pathological gambling associated with cabergoline therapy in a patient with a pituitary prolactinoma. J Neuropsychiatry Clin Neurosci 19:473\u2013474. https:\/\/doi.org\/10.1176\/jnp.2007.19.4.473","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1693_CR24","doi-asserted-by":"publisher","unstructured":"Hinojosa-Amaya JM, Johnson N, Gonz\u00e1lez-Torres C et al (2020) Depression and impulsivity self-assessment tools to identify dopamine agonist side effects in patients with pituitary adenomas. Front Endocrinol 11. https:\/\/doi.org\/10.3389\/fendo.2020.579606","DOI":"10.3389\/fendo.2020.579606"},{"key":"1693_CR25","doi-asserted-by":"publisher","first-page":"111363","DOI":"10.1016\/j.jocn.2025.111363","volume":"138","author":"P Penchev","year":"2025","unstructured":"Penchev P, Milanova-Ilieva D, Gaydarski L et al (2025) Impulse control disorders in prolactinoma patients treated with dopamine agonists: a systematic review and meta-analysis with trial sequential analysis. J Clin Neurosci 138:111363. https:\/\/doi.org\/10.1016\/j.jocn.2025.111363","journal-title":"J Clin Neurosci"},{"key":"1693_CR26","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1007\/s12020-016-1088-1","volume":"55","author":"SMC De Sousa","year":"2017","unstructured":"De Sousa SMC, Chapman IM, Falhammar H, Torpy DJ (2017) Dopa-testotoxicosis: disruptive hypersexuality in hypogonadal men with prolactinomas treated with dopamine agonists. Endocrine 55:618\u2013624. https:\/\/doi.org\/10.1007\/s12020-016-1088-1","journal-title":"Endocrine"},{"key":"1693_CR27","doi-asserted-by":"publisher","first-page":"90","DOI":"10.55940\/medphar202346","volume":"2","author":"KVSS Kumar","year":"2023","unstructured":"Kumar KVSS, Sree SL, Sree SJ (2023) Cabergoline - Dopamine Receptor Agonist. Med Pharm J 2:90\u201398. https:\/\/doi.org\/10.55940\/medphar202346","journal-title":"Med Pharm J"},{"key":"1693_CR28","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1016\/j.neubiorev.2011.03.005","volume":"35","author":"DJ Hayes","year":"2011","unstructured":"Hayes DJ, Greenshaw AJ (2011) 5-HT receptors and reward-related behaviour: A review. Neurosci Biobehavioral Reviews 35:1419\u20131449. https:\/\/doi.org\/10.1016\/j.neubiorev.2011.03.005","journal-title":"Neurosci Biobehavioral Reviews"},{"key":"1693_CR29","doi-asserted-by":"publisher","first-page":"135555","DOI":"10.1016\/j.neulet.2020.135555","volume":"743","author":"J Chu","year":"2021","unstructured":"Chu J, Deyama S, Li X et al (2021) Role of 5-HT1A receptor-mediated serotonergic transmission in the medial prefrontal cortex in acute restraint stress-induced augmentation of rewarding memory of cocaine in mice. Neurosci Lett 743:135555. https:\/\/doi.org\/10.1016\/j.neulet.2020.135555","journal-title":"Neurosci Lett"},{"key":"1693_CR30","doi-asserted-by":"publisher","first-page":"1745","DOI":"10.1007\/s00213-020-05496-x","volume":"237","author":"T Humby","year":"2020","unstructured":"Humby T, Smith GE, Small R et al (2020) Effects of 5-HT2C, 5-HT1A receptor challenges and modafinil on the initiation and persistence of gambling behaviours. Psychopharmacology 237:1745\u20131756. https:\/\/doi.org\/10.1007\/s00213-020-05496-x","journal-title":"Psychopharmacology"},{"key":"1693_CR31","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1007\/s00213-003-1726-1","volume":"173","author":"YP Liu","year":"2004","unstructured":"Liu YP, Wilkinson LS, Robbins TW (2004) Effects of acute and chronic buspirone on impulsive choice and efflux of 5-HT and dopamine in hippocampus, nucleus accumbens and prefrontal cortex. Psychopharmacology 173:175\u2013185. https:\/\/doi.org\/10.1007\/s00213-003-1726-1","journal-title":"Psychopharmacology"},{"key":"1693_CR32","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1016\/j.neulet.2013.10.013","volume":"556","author":"C-L Lu","year":"2013","unstructured":"Lu C-L, Ku Y-C, Lo S-M et al (2013) Acute and subchronic effects of buspirone on attention and impulsivity in the five-choice serial reaction time task in rats. Neurosci Lett 556:210\u2013215. https:\/\/doi.org\/10.1016\/j.neulet.2013.10.013","journal-title":"Neurosci Lett"},{"key":"1693_CR33","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1002\/ajmg.b.31025","volume":"153B","author":"A Benko","year":"2010","unstructured":"Benko A, Lazary J, Molnar E et al (2010) Significant association between the C(\u2013\u20091019)G functional polymorphism of the HTR1A gene and impulsivity. Am J Med Genet Part B: Neuropsychiatric Genet 153B:592\u2013599. https:\/\/doi.org\/10.1002\/ajmg.b.31025","journal-title":"Am J Med Genet Part B: Neuropsychiatric Genet"},{"key":"1693_CR34","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.parkreldis.2018.01.010","volume":"49","author":"XH Castro-Mart\u00ednez","year":"2018","unstructured":"Castro-Mart\u00ednez XH, Garc\u00eda-Ruiz PJ, Mart\u00ednez-Garc\u00eda C et al (2018) Behavioral addictions in early-onset Parkinson disease are associated with DRD3 variants. Parkinsonism Relat Disord 49:100\u2013103. https:\/\/doi.org\/10.1016\/j.parkreldis.2018.01.010","journal-title":"Parkinsonism Relat Disord"},{"key":"1693_CR35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1530\/EJE-12-0198","volume":"167","author":"AP Athanasoulia","year":"2012","unstructured":"Athanasoulia AP, Sievers C, Ising M et al (2012) Polymorphisms of the drug transporter gene ABCB1 predict side effects of treatment with cabergoline in patients with PRL adenomas. Eur J Endocrinol 167:327\u2013335. https:\/\/doi.org\/10.1530\/EJE-12-0198","journal-title":"Eur J Endocrinol"},{"key":"1693_CR36","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/pcn.13511","volume":"77","author":"M Fusaroli","year":"2023","unstructured":"Fusaroli M, Giunchi V, Battini V et al (2023) Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance-pharmacodynamic study. J Neuropsychiatry Clin Neurosci 77:160\u2013167. https:\/\/doi.org\/10.1111\/pcn.13511","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"1693_CR37","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s41983-024-00930-9","volume":"61","author":"H Raji","year":"2025","unstructured":"Raji H, Dinesh S, Sharma S (2025) Inside the impulsive brain: a narrative review on the role of neurobiological, hormonal and genetic factors influencing impulsivity in psychiatric disorders. Egypt J Neurol Psychiatry Neurosurg 61:4. https:\/\/doi.org\/10.1186\/s41983-024-00930-9","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"key":"1693_CR38","doi-asserted-by":"publisher","unstructured":"Kokane SS, Perrotti LI (2020) Sex differences and the role of estradiol in mesolimbic reward circuits and vulnerability to cocaine and opiate addiction. Front Behav Neurosci 14. https:\/\/doi.org\/10.3389\/fnbeh.2020.00074","DOI":"10.3389\/fnbeh.2020.00074"},{"key":"1693_CR39","doi-asserted-by":"publisher","unstructured":"Ramli NZ, Yahaya MF, Mohd Fahami NA et al (2023) Brain volumetric changes in menopausal women and its association with cognitive function: a structured review. Front Aging Neurosci 15. https:\/\/doi.org\/10.3389\/fnagi.2023.1158001","DOI":"10.3389\/fnagi.2023.1158001"},{"key":"1693_CR40","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11920-022-01405-5","volume":"25","author":"C Anaya","year":"2023","unstructured":"Anaya C, Culbert KM, Klump KL (2023) Binge Eating Risk During Midlife and the Menopausal Transition: Sensitivity to Ovarian Hormones as Potential Mechanisms of Risk. Curr Psychiatry Rep 25:45\u201352. https:\/\/doi.org\/10.1007\/s11920-022-01405-5","journal-title":"Curr Psychiatry Rep"},{"key":"1693_CR41","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1139\/apnm-2023-0623","volume":"49","author":"C Vincent","year":"2024","unstructured":"Vincent C, Bodnaruc AM, Prud\u2019homme D et al (2024) Disordered eating behaviours during the menopausal transition: a systematic review. Appl Physiol Nutr Metab 49:1286\u20131308. https:\/\/doi.org\/10.1139\/apnm-2023-0623","journal-title":"Appl Physiol Nutr Metab"},{"key":"1693_CR42","doi-asserted-by":"publisher","first-page":"844718","DOI":"10.3389\/fpsyt.2022.844718","volume":"13","author":"E Correa","year":"2022","unstructured":"Correa E, Castro AC, de Araujo AA, Botelho MC et al (2022) Binge Eating and Compulsive Buying During Cabergoline Treatment for Prolactinoma: A Case Report. Front Psychiatry 13:844718. https:\/\/doi.org\/10.3389\/fpsyt.2022.844718","journal-title":"Front Psychiatry"},{"key":"1693_CR43","doi-asserted-by":"publisher","first-page":"205","DOI":"10.7861\/clinmedicine.14-2-205","volume":"14","author":"VS Premaratne","year":"2014","unstructured":"Premaratne VS, Saeger I, MacDonald BK (2014) Lesson of the month (1): Cabergoline \u2013 \u2018I eat funny on that\u2019. Clin Med (Lond) 14:205\u2013207. https:\/\/doi.org\/10.7861\/clinmedicine.14-2-205","journal-title":"Clin Med (Lond)"},{"key":"1693_CR44","doi-asserted-by":"publisher","first-page":"1671","DOI":"10.1007\/s10571-021-01064-9","volume":"42","author":"M Pourhamzeh","year":"2022","unstructured":"Pourhamzeh M, Moravej FG, Arabi M et al (2022) The Roles of Serotonin in Neuropsychiatric Disorders. Cell Mol Neurobiol 42:1671\u20131692. https:\/\/doi.org\/10.1007\/s10571-021-01064-9","journal-title":"Cell Mol Neurobiol"},{"key":"1693_CR45","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jad.2022.05.114","volume":"311","author":"AV Wilkinson","year":"2022","unstructured":"Wilkinson AV, Swann AC, Graham DP et al (2022) Emotional self-regulation, impulsivity, 5-HTTLPR and tobacco use behavior among psychiatric inpatients. J Affect Disord 311:631\u2013636. https:\/\/doi.org\/10.1016\/j.jad.2022.05.114","journal-title":"J Affect Disord"},{"key":"1693_CR46","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1177\/1756285613476127","volume":"6","author":"TA Mestre","year":"2013","unstructured":"Mestre TA, Strafella AP, Thomsen T et al (2013) Diagnosis and treatment of impulse control disorders in patients with movement disorders. Ther Adv Neurol Disord 6:175\u2013188. https:\/\/doi.org\/10.1177\/1756285613476127","journal-title":"Ther Adv Neurol Disord"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01693-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-026-01693-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-026-01693-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:49:35Z","timestamp":1782409775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-026-01693-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["1693"],"URL":"https:\/\/doi.org\/10.1007\/s11102-026-01693-7","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"3 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"87"}}